Cynvec

About Cynvec

Cynvec is a biotechnology company focused on the development of viral immunotherapies, specifically targeting cancer treatment. The company is pioneering a proprietary experimental therapy based on the Sindbis oncolytic viral vector, which leverages the body's immune system to combat cancer. This innovative approach involves a simple injection that distributes the therapeutic agent throughout the body, targeting tumors effectively. Cynvec's lead candidate, CYN102, is designed to address late-stage ovarian cancer, a condition with limited treatment options. By pairing the Sindbis vector with a tumor-associated antigen, NYESO-1, the therapy aims to stimulate a memory T cell response, crucial for combating aggressive ovarian tumors. The company's research indicates that a significant number of patients do not respond to existing platinum-based therapies, and many experience recurrence. Cynvec's preclinical and clinical developments show promise in overcoming challenges faced by other immune therapies, such as CAR T, by enhancing immune cell infiltration into tumors and increasing the expression of necessary checkpoint proteins and T cell receptors.